Exploiting death receptor signaling pathways for tumor therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1705, Issue 1, 2004, Pages 27-41

  Fulda, Simone ^a   Debatin, Klaus Michael ^a  

^a Children's Hospital   (Germany)

Author keywords

Apoptosis; Cancer; CD95; Death receptor; Resistance; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CASPASE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DACTINOMYCIN; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; FLAVOPIRIDOL; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; MITOMYCIN C; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEASOME INHIBITOR; PROTEIN BCL 2; PURVALANOL A; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; COLORECTAL CANCER; DRUG SAFETY; DRUG TARGETING; GAMMA IRRADIATION; GENE CONTROL; GENE MUTATION; GENETIC CONSERVATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HOMEOSTASIS; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LUNG CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; SUICIDE GENE THERAPY; T CELL LEUKEMIA; TISSUE GROWTH;

ANTIGENS, CD95; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 9944222054     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2004.09.003     Document Type: Review

References (188)

1. I. Herr, and K.M. Debatin Cellular stress response and apoptosis in cancer therapy Blood 98 2001 2603 2614
2. M.O. Hengartner The biochemistry of apoptosis Nature 407 2000 770 776
3. T. Rich, R.L. Allen, and A.H. Wyllie Defying death after DNA damage Nature 40 2000 777 783
4. M. Karin, Y. Cao, F.R. Greten, and Z.W. Li NF-kappaB in cancer: from innocent bystander to major culprit Nature Reviews. Cancer 2 2002 301 310
5. R.J. Davis Signal transduction by the JNK group of MAP kinases Cell 103 2000 239 252
6. A. Degterev, M. Boyce, and J. Yuan A decade of caspases, death and anti-death: tumour resistance to apoptosis Oncogene 22 2003 8543 8567
7. F.H. Igney, and P.H. Krammer Death and anti-death: tumour resistance to apoptosis Nature Reviews. Cancer 2 2002 277 288
8. M. Leist, and M. Jaattela Four deaths and a funeral: from caspases to alternative mechanisms Nature Reviews. Molecular Cell Biology 2 2001 589 598
9. S. Nagata DNA fragmentation Experimental Cell Research 256 2000 12 18
10. A. Ashkenazi, and V.M. Dixit Apoptosis control by death and decoy receptors Current Opinion in Cell Biology 11 1999 255 260
11. G. van Loo, X. Saelens, M. van Gurp, M. MacFarlane, S.J. Martin, and P. Vandenabeele The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet Cell Death and Differentiation 9 2002 1031 1042
12. V. Cowling, and J. Downward Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain Cell Death and Differentiation 9 2002 1046 1056
13. H. Walczak, and P.H. Krammer The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems Experimental Cell Research 256 2000 58 66
14. A. Ashkenazi, and V.M. Dixit Death receptors: signaling and modulation Science 281 1998 1305 1308
15. P.H. Krammer CD95's deadly mission in the immune system Nature 407 2000 789 795
16. F.H. Igney, and P.H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack Journal of Leukocyte Biology 71 2002 907 920
17. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, and C.A. Smith Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
18. S.A. Marsters, R.M. Pitti, C.J. Donahue, S. Ruppert, K.D. Bauer, and A. Ashkenazi Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked CrmA Current Biology 6 1996 750 752
19. G. Pan, K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V.M. Dixit The receptor for the cytotoxic ligand TRAIL Science 276 1997 111 113
20. P.M. Chaudhary, M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway Immunity 7 1997 821 830
21. M. MacFarlane, M. Ahmad, S.M. Srinivasula, T. Fernandes-Alnemri, G.M. Cohen, and E.S. Alnemri Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL Journal of Biological Chemistry 272 1997 25417 25420
22. H. Walczak, M.A. Degli-Esposti, R.S. Johnson, P.J. Smolak, J.Y. Waugh, N. Boiani, M.S. Timour, M.J. Gerhart, K.A. Schooley, C.A. Smith, R.G. Goodwin, and C.T. Rauch TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL EMBO Journal 16 1997 5386 5397
23. G.S. Wu, T.F. Burns, E.R. McDonald III, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, S.R. Hamilton, N.B. Spinner, S. Markowitz, G. Wu, and W.S. el-Deiry KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene Nature Genetics 17 1997 141 143
24. M.A. Degli-Esposti, P.J. Smolak, H. Walczak, J. Waugh, C.P. Huang, R.F. DuBose, R.G. Goodwin, and C.A. Smith Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family Journal of Experimental Medicine 186 1997 1165 1170
25. G. Pan, J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M Dixit An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 1997 815 818
26. S.A. Marsters, J.P. Sheridan, R.M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A.D. Goddard, P. Godowski, and A. Ashkenazi A novel receptor for Apo2L/TRAIL contains a truncated death domain Current Biology 7 1997 1003 1006
27. G. Pan, J. Ni, G. Yu, Y.F. Wei, and V.M. Dixit TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling FEBS Letters 424 1998 41 45
28. M.A. Degli-Esposti, W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 7 1997 813 820
29. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, R. DiPrinzio, R.A. Dodds, I.E. James, M. Rosenberg, J.C. Lee, and P.R. Young Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL Journal of Biological Chemistry 273 1998 14363 14367
30. F.G. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer, and M.E. Peter Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO Journal 14 1995 5579 5588
31. B.C. Barnhart, J.C. Lee, E.C. Alappat, and M.E. Peter The death effector domain protein family, death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 Oncogene 22 2003 8634 8644
32. F.C. Kischkel, D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, and A. Ashkenazi Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 Journal of Biological Chemistry 276 2001 46639 46646
33. M.R. Sprick, E. Rieser, H. Stahl, A. Grosse-Wilde, M.A. Weigand, and H. Walczak Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but cannot functionally substitute caspase-8 EMBO Journal 21 2002 4520 4530
34. C. Scaffidi, S. Fulda, A. Srinivasan, C. Friesen, F. Li, K.J. Tomaselli, K.M. Debatin, P.H. Krammer, and M.E. Peter Two CD95 (APO-1/Fas) signaling pathways EMBO Journal 17 1998 1675 1687
35. S. Fulda, E. Meyer, C. Friesen, S.A. Susin, G. Kroemer, and K.M. Debatin Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis Oncogene 20 2001 1063 1075
36. M. Grell, G. Zimmermann, E. Gottfried, C.M. Chen, U. Grunwald, D.C. Huang, Y.H. Wu Lee, H. Durkop, H. Engelmann, P. Scheurich, H. Wajant, and A. Strasser Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF EMBO Journal 18 1999 3034 3043
37. C. Friesen, I. Herr, P.H. Krammer, and K.M. Debatin Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells Nature Medicine 2 1996 574 577
38. S. Fulda, M.U. Kufer, E. Meyer, F. van Valen, B. Dockhorn-Dworniczak, and K.M. Debatin Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Oncogene 20 2001 5865 5877
39. M. Muller, S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W.J. Hofmann, W. Stremmel, P.H. Krammer, and P.R. Galle Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 Journal of Clinical Investigation 99 1997 403 413
40. M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S.L. Friedman, P.R. Galle, W. Stremmel, M. Oren, and P.H. Krammer p53 Activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs Journal of Experimental Medicine 188 1998 2033 2045
41. J.A. Houghton, F.G. Harwood, and D.M. Tillman Thymineless death in colon carcinoma cells is mediated via-Fas-signaling Proceedings of the National Academy of Sciences 94 1997 8144 8149
42. E.A. Reap, K. Roof, K. Maynor, M. Borrero, J. Booker, and P.L. Cohen Radiation and stress-induced apoptosis: a role for Fas/Fas ligand-interactions Proceedings of the National Academy of Sciences 94 1997 5750 5755
43. S. Kasibhatla, T. Brunner, L. Genestier, F. Echeverri, A. Mahboubi, and D.R. Green DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1 Molecular Cell 1 1998 543 551
44. O. Micheau, A. Hammann, E. Solary, and M.T. Dimanche-boitrel Stat-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs Biochemical and Biophysical Research Communications 1999 256
45. C.M. Eischen, T.J. Kottke, L.M. Martins, G.S. Basi, J.S. Tung, W.C. Earnshaw, P.J. Leibson, and S.H. Kaufmann Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions Blood 90 1997 935 943
46. I. Petak, and J.A. Houghton Shared pathways: death receptors and cytotoxic drugs in cancer therapy Pathology Oncology Research 7 2001 95 106
47. A. Villunger, A. Egle, M. Kos, B.L. Hartmann, S. Geley, R. Kofler, and R. Greil Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells Cancer Research 57 1997 3331 3334
48. I.H. Engels, A. Stepczynska, C. Stroh, K. Lauber, C. Berg, R. Schwenzer, H. Wajant, R.U. Janicke, A.G. Porter, C. Belka, M. Gregor, K. Schulze-Osthoff, and S. Wesselborg Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis Oncogene 19 2000 4563 4573
49. T. Kataoka, M. Schroter, M. Hahne, P. Schneider, M. Irmler, M. Thome, C.J. Froelich, and J. Tschopp FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme b, chemotherapeutic drugs, and gamma irradiation Journal of Immunology 161 1998 3936 3942
50. W.C. Yeh, J.L. Pompa, M.E. McCurrach, H.B. Shu, A.J. Elia, A. Shahinian, M. Ng, A. Wakeham, W. Khoo, K. Mitchell, W.S. El-Deiry, S.W. Lowe, D.V. Goeddel, and T.W. Mak FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis Science 279 1998 1954 1958
51. H. LeBlanc, D. Lawrence, E. Varfolomeev, K. Totpal, J. Morlan, P. Schow, S. Fong, R. Schwall, D. Sinicropi, and A. Ashkenazi Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax Nature Medicine 8 2002 274 281
52. M.L. Hyer, C. Voelkel-Johnson, S. Rubinchik, J. Dong, and J.S. Norris Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis Molecular Therapy. The Journal of the American Society of Gene Therapy 2 2000 348 358
53. P. Lassus, X. Opitz-Araya, and Y. Lazebnik Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization Science 297 2002 1352 1354
54. V.S. Marsden, L. O'Connor, L.A. O'Reilly, J. Silke, D. Metcalf, P.G. Ekert, D.C. Huang, F. Cecconi, K. Kuida, K.J. Tomaselli, S. Roy, D.W. Nicholson, D.L. Vaux, P. Bouillet, J.M. Adams, and A. Strasser Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome Nature 419 2002 634 637
55. H.N. LeBlanc, and A. Ashkenazi Apo-2L/TRAIL and its death and decoy resceptors Cell Death and Differentiation 10 2003 66 75
56. H. Wajant, K. Pfizenmaier, and P. Scheurich TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy Apoptosis 7 2002 449 459
57. H. Walczak, and P.H. Krammer The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems Experimental Cell Research 256 2000 58 66
58. N. Ozoren, and W.S. El-Deiry Cell surface death receptor signaling in normal and cancer cells Seminars in Cancer Biology 13 2003 135 147
59. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand Journal of Clinical Investigation 104 1999 155 162
60. D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C.A. Smith, S.S. Strom, S. Kelley, J.A. Fox, D. Thomas, and A. Ashkenazi Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nature Medicine 7 2001 383 385
61. M. Jo, T.H. Kim, D.W. Seol, J.E. Esplen, K. Dorko, T.R. Billiar, and S.C. Strom Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nature Medicine 6 2000 564 567
62. R. Nitsch, I. Bechmann, R.A. Deisz, D. Haas, T.N. Lehmann, U. Wendling, and F. Zipp Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) Lancet 356 2000 827 828
63. H. Erhardt, S. Fulda, I. Schmid, J. Hiscott, K.M. Debatin, and I. Jeremias TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB Oncogene 22 2003 3842 3852
64. M.J. Smyth, K. Takeda, Y. Hayakawa, J.J. Peschon, M.R. van den Brink, and H. Yagita Nature's TRAIL-on a path to cancer immunotherapy Immunity 18 2003 1 6
65. E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, and M.J. Smyth Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice Journal of Immunology 168 2002 1356 1361
66. K. Takeda, Y. Hayakawa, M.J. Smyth, N. Kayagaki, N. Yamaguchi, S. Kakuta, Y. Iwakura, H. Yagita, and K. Okumura Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nature Medicine 7 2001 94 100
67. M.J. Smyth, E. Cretney, K. Takeda, R.H. Wiltrout, L.M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis Journal of Experimental Medicine 193 2001 661 670
68. C. Friesen, S. Fulda, and K.M. Debatin Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells Leukemia 11 1997 1833 1841
69. S. Fulda, M. Los, C. Friesen, and K.M. Debatin Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system International Journal of Cancer 76 1998 105 114
70. S. Strand, W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Medicine 2 1996 1361 1366
71. P. Moller, K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P.H. Krammer Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium International Journal of Cancer 57 1994 371 377
72. M.S. Shin, W.S. Park, S.Y. Kim, H.S. Kim, S.J. Kang, K.Y. Song, J.Y. Park, S.M. Dong, J.H. Pi, R.R. Oh, J.Y. Lee, N.J. Yoo, and S.H. Lee Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma American Journal of Pathology 154 1999 1785 1791
73. Z. Jin, E.R.I. McDonald, D.T. Dicker, and W.S. El-Deiry Deficient TRAIL death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis Journal of Biological Chemistry 2004 M405538200
74. K.M. Debatin, K. Stahnke, and S. Fulda Apoptosis in hematological disorders Seminars in Cancer Biology 13 2003 149 158
75. T. Maeda, Y. Yamada, R. Moriuchi, K. Sugahara, K. Tsuruda, T. Joh, S. Atogami, K. Tsukasaki, M. Tomonaga, and S. Kamihira Fas gene mutation in the progression of adult T cell leukemia Journal of Experimental Medicine 189 1999 1063 1071
76. T.H. Landowski, N. Qu, I. Buyuksal, J.S. Painter, and W.S. Dalton Mutations in the Fas antigen in patients with multiple myeloma Blood 90 1997 4266 4270
77. S. Wohlfart, D. Sebinger, P. Gruber, J. Buch, D. Polgar, G. Krupitza, M. Rosner, M. Hengstschlager, M. Raderer, A. Chott, and L. Mullauer FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma American Journal of Pathology 164 2004 1081 1089
78. L. Shen, A.C.T. Liang, L. Lu, W.Y. Au, Y.-L. Kwong, R.H.S. Liang, and G. Srivastava Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-Cell lymphoma American Journal of Pathology 161 2002 2123 2131
79. A. Ashkenazi, and V.M. Dixit Apoptosis control by death and decoy receptors Current Opinion in Cell Biology 11 1999 255 260
80. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients Clinical Cancer Research 7 2001 1282 1286
81. G.P. Midis, Y. Shen, and L.B. Owen-Schaub Elevated soluble Fas (sFas) levels in non hematopoietic human malignancy Cancer Research 56 1996 3870 3874
82. W. Roth, S. Isenmann, M. Nakamura, M. Platten, W. Wick, P. Kleihues, M. Bahr, H. Ohgaki, A. Ashkenazi, and M. Weller Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis Cancer Research 61 2001 2759 2765
83. R.M. Pitti, S.A. Marsters, D.A. Lawrence, M. Roy, F.C. Kischkel, P. Dowd, A. Huang, C.J. Donahue, S.W. Sherwood, D.T. Baldwin, P.J. Godowski, W.I. Wood, A.L. Gurney, K.J. Hillan, R.L. Cohen, A.D. Goddard, D. Botstein, and A. Ashkenazi Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 396 1998 699 703
84. M.S. Sheikh, Y. Huang, E.A. Fernandez-Salas, W.S. El-Deiry, H. Friess, S. Amundson, J. Yin, S.J. Meltzer, N.J. Holbrook, and A.J. Fornace Jr. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract Oncogene 18 1999 4153 4159
85. M.J. Dechant, J. Fellenberg, C.G. Scheuerpflug, V. Ewerbeck, and K.M. Debatin Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines International Journal of Cancer 109 2004 661 667
86. S.H. Lee, M.S. Shin, H.S. Kim, H.K. Lee, W.S. Park, S.Y. Kim, J.H. Lee, S.Y. Han, J.Y. Park, R.R. Oh, C.S. Kang, K.M. Kim, J.J. Jang, S.W. Nam, J.Y. Lee, and N.J. Yoo Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines Oncogene 20 2001 399 403
87. S.H. Lee, M.S. Shin, H.S. Kim, H.K. Lee, W.S. Park, S.Y. Kim, J.H. Lee, S.Y. Han, J.Y. Park, R.R. Oh, J.J. Jang, J.Y. Han, J.Y. Lee, and N.J. Yoo Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers Cancer Research 59 1999 5683 5686
88. T. Arai, Y. Akiyama, S. Okabe, K. Saito, T. Iwai, and Y. Yuasa Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas Cancer Letters 133 1998 197 204
89. M.S. Shin, H.S. Kim, S.H. Lee, W.S. Park, S.Y. Kim, J.Y. Park, J.H. Lee, S.K. Lee, S.N. Lee, S.S. Jung, J.Y. Han, H. Kim, J.Y. Lee, and N.J. Yoo Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers Cancer Research 61 2001 4942 4946
90. S.I. Pai, G.S. Wu, N. Ozoren, L. Wu, J. Jen, D. Sidransky, and W.S. El-Deiry Rare loss-of-function mutation of a death receptor gene in head and neck cancer Cancer Research 58 1998 3513 3518
91. S.B. Baylin Mechanisms underlying epigenetically mediated gene silencing in cancer Seminars in Cancer Biology 12 2002 331 337
92. M.M. van Noesel, S. van Bezouw, P.A. Voute, J.G. Herman, R. Pieters, and R. Versteeg Clustering of hypermethylated genes in neuroblastoma Genes, Chromosomes and Cancer 38 2003 226 233
93. H.L. Maecker, Z. Yun, H.T. Maecker, and A.J. Giaccia Epigenetic changes in tumor Fas levels determine immune escape and response to therapy Cancer Cell 2 2002 139 148
94. I. Petak, R.P. Danam, D.M. Tillman, R. Vernes, S.R. Howell, L. Berczi, L. Kopper, T.P. Brent, and J.A. Houghton Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma Cell Death and Differentiation 10 2003 211 217
95. P. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly Histone deacetylases and cancer: causes and therapies Nature Reviews. Cancer 1 2001 194 202
96. J. Peli, M. Schroter, C. Rudaz, M. Hahne, C. Meyer, E. Reichmann, and J. Tschopp Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas EMBO Journal 18 1999 1824 1831
97. V.N. Ivanov, A. Bhoumik, M. Krasilnikov, R. Raz, L.B. Owen-Schaub, D. Levy, C.M. Horvath, and Z. Ronai Cooperation between STAT3 and c-Jun suppresses Fas transcription Molecular Cell 7 2001 517 528
98. A. Krueger, S. Baumann, P.H. Krammer, and S. Kirchhoff FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis Molecular and Cellular Biology 21 2001 8247 8254
99. S. Fulda, E. Meyer, and K.-M. Debatin Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression Cancer Research 60 2000 3947 3956
100. X.D. Zhang, A. Franco, K. Myers, C. Gray, T. Nguyen, and P. Hersey Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Cancer Research 59 1999 2747 2753
101. M. Sturzl, C. Hohenadl, C. Zietz, E. Castanos-Velez, A. Wunderlich, G. Ascherl, P. Biberfeld, P. Monini, P.J. Browning, and B. Ensoli Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells Journal of the National Cancer Institute 91 1999 1725 1733
102. A. Dutton, J.D. O'Neil, A.E. Milner, G.M. Reynolds, J. Starczynski, J. Crocker, L.S. Young, and P.G. Murray Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death Proceedings of the National Academy of Sciences 101 2004 6611 6616
103. S. Mathas, A. Lietz, I. Anagnostopoulos, F. Hummel, B. Wiesner, M. Janz, F. Jundt, B. Hirsch, K. Johrens-Leder, H.-P. Vornlocher, K. Bommert, H. Stein, and B. Dorken c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis J. Experimental Medicine 199 2004 1041 1052
104. J.P. Medema, J. de Jong, T. van Hall, C.J. Melief, and R. Offringa Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein Journal of Experimental Medicine 190 1999 1033 1038
105. M. Djerbi, V. Screpanti, A.I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors Journal of Experimental Medicine 190 1999 1025 1032
106. H. Kinoshita, H. Yoshikawa, K. Shiiki, Y. Hamada, Y. Nakajima, and K. Tasaka Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression International Journal of Cancer 88 2000 986 991
107. D.W. Chang, Z. Xing, Y. Pan, A. Algeciras-Schimnich, B.C. Barnhart, S. Yaish-Ohad, M.E. Peter, and X. Yang c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis EMBO Journal 21 2002 3704 3714
108. C. Hao, F. Beguinot, G. Condorelli, A. Trencia, E.G. Van Meir, V.W. Yong, I.F. Parney, W.H. Roa, and K.C. Petruk Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells Cancer Research 61 2001 1162 1170
109. C. Xiao, B.F. Yang, N. Asadi, F. Beguinot, and C. Hao Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells Journal of Biological Chemistry 277 2002 25020 25025
110. S. Mandruzzato, F. Brasseur, G. Andry, T. Boon, and P.V.D. Bruggen A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma Journal of Experimental Medicine 186 1997 785 793
111. H. Kim, J. Lee, Y. Soung, W. Park, S. Kim, J. Lee, J. Park, Y. Cho, C. Kim, S.D.D. Jeong, S. Nam, S. Kim, J. Lee, N. Yoo, and S. Lee Inactivating mutations of caspase-8 gene in colorectal carcinomas Gastroenterology 125 2003 708 715
112. T. Teitz, T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet, V.A. Valentine, F.G. Behm, A.T. Look, J.M. Lahti, and V.J. Kidd Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN Nature Medicine 6 2000 529 535
113. S. Hopkins-Donaldson, A. Ziegler, S. Kurtz, C. Bigosch, D. Kandioler, C. Ludwig, U. Zangemeister-Wittke, and R. Stahel Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation Cell Death and Differentiation 10 2003 356 364
114. C. Pingoud-Meier, D. Lang, A.J. Janss, L.B. Rorke, P.C. Phillips, T. Shalaby, and M.A. Grotzer Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma Clinical Cancer Research 9 2003 6401 6409
115. K. Harada, S. Toyooka, N. Shivapurkar, A. Maitra, J.L. Reddy, H. Matta, K. Miyajima, C.F. Timmons, G.E. Tomlinson, D. Mastrangelo, R.J. Hay, P.M. Chaudhary, and A.F. Gazdar Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines Cancer Research 62 2002 5897 5901
116. S. Fulda, and K.M. Debatin IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway Oncogene 21 2002 2295 2308
117. X. Yang, M.S. Merchant, M.E. Romero, M. Tsokos, L.H. Wexler, U. Kontny, C.L. Mackall, and C.J. Thiele Cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB Cancer Research 63 2003 1122 1129
118. B. Banelli, I. Casciano, M. Croce, A. Di Vinci, I. Gelvi, G. Pagnan, C. Brignole, G. Allemanni, S. Ferrini, M. Ponzoni, and M. Romani Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region Nature Medicine 8 2002 1333 1335 (author reply 1335)
119. G.S. Salvesen, and C.S. Duckett IAP proteins: blocking the road to death's door Nature Reviews. Molecular Cell Biology 3 2002 401 410
120. D.C. Altieri Validating survivin as a cancer therapeutic target Nature Reviews. Cancer 3 2003 46 54
121. V.E. Velculescu, S.L. Madden, L. Zhang, A.E. Lash, J. Yu, C. Rago, A. Lal, C.J. Wang, G.A. Beaudry, K.M. Ciriello, B.P. Cook, M.R. Dufault, A.T. Ferguson, Y. Gao, T.C. He, H. Hermeking, S.K. Hiraldo, P.M. Hwang, M.A. Lopez, H.F. Luderer, B. Mathews, J.M. Petroziello, K. Polyak, L. Zawel, and K.W. Kinzler Analysis of human transcriptomes Nature Genetics 23 1999 387 388
122. J. Dierlamm, M. Baens, I. Wlodarska, M. Stefanova-Ouzounova, J.M. Hernandez, D.K. Hossfeld, C. De Wolf-Peeters, A. Hagemeijer, H. Van den Berghe, and P. Marynen The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18) (q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas Blood 93 1999 3601 3609
123. P. Hersey, and X.D. Zhang How melanoma cells evade trail-induced apoptosis Nature Reviews. Cancer 1 2001 142 150
124. Z. Song, X. Yao, and M. Wu Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis Journal of Biological Chemistry 278 2003 23130 23140
125. O.P. Blanc-Brude, M. Mesri, N.R. Wall, J. Plescia, T. Dohi, and D.C. Altieri Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis Clinical Cancer Research 9 2003 2683 2692
126. T. Liu, B. Brouha, and D. Grossman Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells Oncogene 23 2004 39 48
127. G. van Loo, X. Saelens, M. van Gurp, M. MacFarlane, S.J. Martin, and P. Vandenabeele The role of mitochondrial factors in apoptosis: a russian roulette with more than one bullet Cell Death and Differentiation 9 2002 1031 1042
128. C. Du, M. Fang, Y. Li, L. Li, and X. Wang Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition Cell 102 2000 33 42
129. P. Liston, W.G. Fong, N.L. Kelly, S. Toji, T. Miyazaki, D. Conte, K. Tamai, C.G. Craig, M.W. McBurney, and R.G. Korneluk Identification of XAF1 as an antagonist of XIAP anti-caspase activity Nature Cell Biology 3 2001 128 133
130. W.G. Fong, P. Liston, E. Rajcan-Separovic, M. St. Jean, C. Craig, and R.G. Korneluk Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines Genomics 70 2000 113 122
131. D.-S. Byun, K. Cho, B.-K. Ryu, M.-G. Lee, M.-J. Kang, H.-R. Kim, and S.-G. Chi Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas Cancer Research 63 2003 7068 7075
132. E.J. Schlette, L.J. Medeiros, A. Goy, R. Lai, and G.Z. Rassidakis Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma Journal of Clinical Oncology 22 2004 1682 1688
133. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri Anti-apoptosis gene, survivin, and prognosis of neuroblastoma Lancet 351 1998 882 883
134. C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, G. Salles, D.C. Altieri, and T.J. Molina Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood 96 2000 1921 1925
135. P. Wurl, M. Kappler, A. Meye, F. Bartel, T. Kohler, C. Lautenschlager, M. Bache, H. Schmidt, and H. Taubert Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma Lancet 359 2002 943 945
136. A. Chakravarti, E. Noll, P.M. Black, D.F. Finkelstein, N.J. Dyson, and J.S. Loeffler Quantitatively determined survivin expression levels are of prognostic value in human gliomas Journal of Clinical Oncology 20 2002 1063 1068
137. A.I. Sarela, R.C. Macadam, S.M. Farmery, A.F. Markham, and P.J. Guillou Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma Gut 46 2000 645 650
138. A.I. Sarela, C.S. Verbeke, J. Ramsdale, C.L. Davies, A.F. Markham, and P.J. Guillou Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma British Journal of Cancer 86 2002 886 892
139. M. Monzo, R. Rosell, E. Felip, J. Astudillo, J.J. Sanchez, J. Maestre, C. Martin, A. Font, A. Barnadas, and A. Abad A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers Journal of Clinical Oncology 17 1999 2100
140. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clinical Cancer Research 6 2000 127 134
141. S.M. Kennedy, L. O'Driscoll, R. Purcell, R.N. Fitz-Simons, E.W. McDermott, A.D. Hill, N.J. O'Higgins, M. Parkinson, R. Linehan, and M. Clynes Prognostic importance of survivin in breast cancer British Journal of Cancer 88 2003 1077 1083
142. I. Tamm, M. Trepel, M. Cardo-Vila, Y. Sun, K. Welsh, E. Cabezas, A. Swatterthwait, W. Arap, J.C. Reed, and R. Pasqualini Peptides targeting caspase inhibitors Journal of Biological Chemistry 278 2003 14401 14405
143. B.Z. Carter, S.M. Kornblau, T. Tsao, R.-Y. Wang, W.D. Schober, M. Milella, H.-G. Sung, J.C. Reed, and M. Andreeff Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis Blood 102 2003 4179 4186
144. C.G. Ferreira, P. van der Valk, S.W. Span, I. Ludwig, E.F. Smit, F.A.E. Kruyt, H.M. Pinedo, H. van Tinteren, and G. Giaccone Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients Clinical Cancer Research 7 2001 2468 2474
145. S. Cory, and J.M. Adams The Bcl2 family: regulators of the cellular life-or-death switch Nature Reviews. Cancer 2 2002 647 656
146. A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, M.J. Ausserlechner, J.M. Adams, and A. Strasser p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa Science 302 2003 1036 1038
147. E.H.Y. Cheng, T.V. Sheiko, J.K. Fisher, W.J. Craigen, and S.J. Korsmeyer VDAC2 inhibits BAK activation and mitochondrial apoptosis Science 301 2003 513 517
148. G.I. Evan, and K.H. Vousden Proliferation, cell cycle and apoptosis in cancer Nature 411 2001 342 348
149. Y. Deng, Y. Lin, and X. Wu TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO Genes & Development 16 2002 33 45
150. F.R. Greten, C.K. Weber, T.F. Greten, G. Schneider, M. Wagner, G. Adler, and R.M. Schmid Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis Gastroenterology 123 2002 2052 2063
151. P. Aza-Blanc, C.L. Cooper, K. Wagner, S. Batalov, Q.L. Deveraux, and M.P. Cooke Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening Molecular Cell 12 2003 627 637
152. Y. Wang, I.H. Engels, D.A. Knee, M. Nasoff, Q.L. Deveraux, and K.C. Quon Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway Cancer Cell 5 2004 501 512
153. A. Algeciras-Schimnich, E.M. Pietras, B.C. Barnhart, P. Legembre, S. Vijayan, S.L. Holbeck, and M.E. Peter Two CD95 tumor classes with different sensitivities to antitumor drugs Proceedings of the National Academy of Sciences of the United States of America 100 2003 11445 11450
154. A. Ashkenazi Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nature Reviews. Cancer 2 2002 420 430
155. W.S. El-Deiry Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling Cell Death and Differentiation 8 2001 1066 1075
156. A. Chuntharapai, K. Dodge, K. Grimmer, K. Schroeder, S.A. Marsters, H. Koeppen, A. Ashkenazi, and K.J. Kim Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 Journal of Immunology 166 2001 4891 4898
157. K. Ichikawa, W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J.D. Mountz, W.J. Koopman, R.P. Kimberly, and T. Zhou Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nature Medicine 7 2001 954 960
158. K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J.E. Tanner, T.J. Sayers, N. Seki, K. Okumura, H. Yagita, and M.J. Smyth Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy Journal of Experimental Medicine 199 2004 437 448
159. T. Lin, X. Huang, J. Gu, L. Zhang, J.A. Roth, M. Xiong, S.A. Curley, Y. Yu, K.K. Hunt, and B. Fang Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells Oncogene 21 2002 8020 8028
160. J. Lee, M. Hampl, P. Albert, and H.A. Fine Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector Neoplasia (New York) 4 2002 312 323
161. T.A. Rohn, B. Wagenknecht, W. Roth, U. Naumann, E. Gulbins, P.H. Krammer, H. Walczak, and M. Weller CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release Oncogene 20 2001 4128 4137
162. M. Nagane, G. Pan, J.J. Weddle, V.M. Dixit, W.K. Cavenee, and H.J. Huang Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo Cancer Research 60 2000 847 853
163. B. Gliniak, and T. Le Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11 Cancer Research 59 1999 6153 6158
164. M.M. Keane, Y. Rubinstein, M. Cuello, S.A. Ettenberg, P. Banerjee, M.M. Nau, and S. Lipkowitz Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines Breast Cancer Research and Treatment 64 2000 211 219
165. C. Belka, B. Schmid, P. Marini, E. Durand, J. Rudner, H. Faltin, M. Bamberg, K. Schulze-Osthoff, and W. Budach Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL Oncogene 20 2001 2190 2196
166. A.M. Chinnaiyan, U. Prasad, S. Shankar, D.A. Hamstra, M. Shanaiah, T.L. Chenevert, B.D. Ross, and A. Rehemtulla Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proceedings of the National Academy of Sciences of the United States of America 97 2000 1754 1759
167. T.R. Singh, S. Shankar, X. Chen, M. Asim, and R.K. Srivastava Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo Cancer Research 63 2003 5390 5400
168. S. Ray, and A. Almasan Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11 Cancer Research 63 2003 4713 4723
169. R.D. Meng, and W.S. El-Deiry p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma Experimental Cell Research 262 2001 154 169
170. R. Takimoto, and W.S. El-Deiry Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site Oncogene 19 2000 1735 1743
171. S. Wang, and W.S. El-Deiry Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy Proceedings of the National Academy of Sciences 100 2003 15095 15100
172. S. Lacour, O. Micheau, A. Hammann, V. Drouineaud, J. Tschopp, E. Solary, and M.T. Dimanche-Boitrel Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells Oncogene 22 2003 1807 1816
173. S. Fulda, E. Meyer, and K.M. Debatin Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression Cancer Research 60 2000 3947 3956
174. Y. Kim, N. Suh, M. Sporn, and J.C. Reed An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis Journal of Biological Chemistry 277 2002 22320 22329
175. T.J. Sayers, A.D. Brooks, C.Y. Koh, W. Ma, N. Seki, A. Raziuddin, B.R. Blazar, X. Zhang, P.J. Elliott, and W.J. Murphy The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Blood 102 2003 303 310
176. I.M. Pedersen, J.M. Zapata, T. Samuel, F.L. Scott, G.S. Salvesen, T. Honda, G.W. Gribble, N. Suh, M.B. Sporn, T.J. Kipps, and J.C. Reed The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells Blood 2003-11-3774 2004
177. L. Yang, Z. Cao, H. Yan, and W.C. Wood Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy Cancer Research 63 2003 6815 6824
178. N.S. Williams, R.B. Gaynor, S. Scoggin, U. Verma, T. Gokaslan, C. Simmang, J. Fleming, D. Tavana, E. Frenkel, and C. Becerra Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference Clinical Cancer Research 9 2003 931 946
179. D.C. Altieri Survivin, versatile modulation of cell division and apoptosis in cancer Oncogene 22 2003 8581 8589
180. D. Grossman, P.J. Kim, J.S. Schechner, and D.C. Altieri Inhibition of melanoma tumor growth in vivo by survivin targeting Proceedings of the National Academy of Sciences 98 2001 635 640
181. D.S. O'Connor, N.R. Wall, A.C. Porter, and D.C. Altieri p34(cdc2) survival checkpoint in cancer Cancer Cell 2 2002 43 54
182. N.R. Wall, D.S. O'Connor, J. Plescia, Y. Pommier, and D.C. Altieri Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis Cancer Research 63 2003 230 235
183. V. Pisarev, B. Yu, R. Salup, S. Sherman, D.C. Altieri, and D.I. Gabrilovich Full-length dominant-negative survivin for cancer immunotherapy Clinical Cancer Research 9 2003 6523 6533
184. S.M. Schmidt, K. Schag, M.R. Muller, M.M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells Blood 102 2003 571 576
185. M. Schmitz, P. Diestelkoetter, B. Weigle, F. Schmachtenberg, S. Stevanovic, D. Ockert, H.-G. Rammensee, and E.P. Rieber Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides Cancer Research 60 2000 4845 4849
186. S. Fulda, W. Wick, M. Weller, and K.M. Debatin Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Nature Medicine 8 2002 808 815
187. A.D. Schimmer, K. Welsh, C. Pinilla, Z. Wang, M. Krajewska, M.J. Bonneau, I.M. Pedersen, S. Kitada, F.L. Scott, B. Bailly-Maitre, G. Glinsky, D. Scudiero, E. Sausville, G. Salvesen, A. Nefzi, J.M. Ostresh, R.A. Houghten, and J.C. Reed Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity Cancer Cell 5 2004 25 35
188. W.-X. Zong, D. Ditsworth, D.E. Bauer, Z.-Q. Wang, and C.B. Thompson Alkylating DNA damage stimulates a regulated form of necrotic cell death Genes & Development 18 2004 1272 1282